Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Comment by gebremeskelon Jun 13, 2022 2:10pm
303 Views
Post# 34752728

RE:RE:RE:RE:RE:RE:RE:Deliberate Obfuscation

RE:RE:RE:RE:RE:RE:RE:Deliberate ObfuscationTLD1433 is not a done deal yet. Everybody is analysing and re-analysing the data  to try and make the case that Theralase has outdone all possible NMIBC competition and BTD & AA are just around the corner. But we don't have the data yet. And no amount of hand-wringing about "getting paid" is going to change anything. If the numbers are good we get BTD & AA and we're all happy campers. If not we wait a couple more years for the end of the trial while our investment gets more diluted and rutherrin trials move off into the vapour. Nothing is proven until we get substantial durable response rates for a significant number of patients. That's someting the brutes in big pharma will understand.

Rumpl3StiltSkin wrote: I dunno Laser,

1433/TLT has proven itself to the investors on this board. Seems pharmas still have their heads up their butts on this, thinking instead about pills and immuno-therapy and vaccines. Other traditional drug approaches that usually only pan out 15% of the time.

TLT is soo close isn't it? It is maddening! :-) They may show a real threat against Covid this year. They should show the world next year that Rutherrin/PDT is the way forwards for Cancer.

LaserStock29 wrote:
Legit62 wrote: Totally agree Infinity, i think we are just at the beginning of knowing what TLD1433 can really do, i am a long holder and have accumulated many shares like all of you long holders and am also hoping we dont sell ourselves short, also think we are within 6 months of BTD and AA, am curious to see what is presented on the 27TH and at AGM, also would like to know more about The Li Ka Shing relationship, cause as Skyes1 says , he believes this holds the key to our moving foward . 


Osmium molecules 2017

Roger Dumoulin-White, President and CEO of Theralase stated that, “Theralase is committed to expanding our Phase Ib clinical research program to include new oncological targets, using both our Ruthenium (TLD-1433) and Osmium ((TLD-1822, TLD-1824 and TLD-1829) based PDCs. We look forward to presenting this research to the international scientific and medical communities.”

1633 15% more gbm

Sherri McFarland, Ph.D., Professor, Department of Chemistry and Biochemistry, The University of North Carolina at Greensboro stated that, “TLD-1633 is a natural progression of the research work completed by our research labs in the development of TLD-1433. TLD-1633 has shown even stronger safety and efficacy in our labs than TLD-1433, and I am delighted to work with Theralase to optimize and expand their licenced PDC program, as we embark on additional cancer indications.”



Were you guys asleep for 5 years...... 

This whole thing..... oh the TLD-1433... we're just at the beginning.......... NO... we are at the END of Tld-1433........ 

It's time to get PAID for Bladder and move into Ruthenium and other molecules... 

Do a massive licensing or buyout for ACT and the technology....... 

Photodynamic therapy has proven it's 'matured' to become attractive to big pharma. 



 




<< Previous
Bullboard Posts
Next >>